BCAX files Form 144 to sell 5,500 shares

BCAX submitted a Form 144 reporting 5,500 shares of Common Stock to be sold on 04/27/2026 following an exercise of stock options.

Rhea-AI Filing Summary

BCAX submitted a Form 144 reporting 5,500 shares of Common Stock to be sold on 04/27/2026 following an exercise of stock options. The sale is listed through UBS Financial Services Inc. and is to be for cash. The filing also lists prior sales by David Raben in March 2026: 200 shares on 03/03/2026 for $3,690.00, 16,300 shares on 03/04/2026 for $301,920.01, and 5,500 shares on 03/25/2026 for $104,229.40.

Insights

Securities Compliance Counsel

Routine Rule 144 notice for affiliate sale; records prior March trades.

Form 144 is a notice required under Rule 144 when affiliates propose to sell restricted or control securities. This filing lists a planned sale of 5,500 shares after an option exercise, with a broker-dealer intermediary named.

Timing and final execution depend on broker handling and regulatory compliance; subsequent Form 4 or broker reports may show completed transactions.

Key Figures

Shares listed for sale: 5,500 shares Prior sale - Mar 3: 200 shares Prior sale - Mar 4: 16,300 shares +1 more

4 metrics

Shares listed for sale 5,500 shares to be sold on 04/27/2026 following exercise of stock options

Prior sale - Mar 3 200 shares sold on 03/03/2026 for $3,690.00

Prior sale - Mar 4 16,300 shares sold on 03/04/2026 for $301,920.01

Prior sale - Mar 25 5,500 shares sold on 03/25/2026 for $104,229.40

Key Terms

Form 144, exercise of stock options, issuer, broker-dealer

4 terms

Form 144 regulatory

"submitted a Form 144 reporting 5,500 shares to be sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

exercise of stock options financial

"to be sold on 04/27/2026 following an exercise of stock options"

issuer regulatory

"Issuer | | | 5500 | 04/27/2026 | Cash"

broker-dealer financial

"UBS Financial Services Inc. 11 Madison Avenue 4th Floor New York"

A broker-dealer is a licensed firm or individual that both executes trades on behalf of clients (acting as a broker) and buys or sells securities for its own account (acting as a dealer). Investors care because broker-dealers provide the plumbing of markets — they place orders, hold or move cash and securities, offer research or advice, and their stability and fees directly affect trade execution, costs, and the safety of client funds; think of them as a combined travel agent and taxi for your investments.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BCAX's Form 144 report?

It reports a proposed sale of 5,500 common shares on 04/27/2026 following an exercise of stock options. The filing names UBS Financial Services Inc. as the broker/dealer handling the sale.

Who is the selling party named in the BCAX filing?

The filing lists prior sales by David Raben and shows the proposed sale transacted through UBS Financial Services Inc.. The document identifies Raben by name and address in the sale history.

What prior transactions are shown in the Form 144 for BCAX?

The filing records three March 2026 sales by David Raben: 200 shares on 03/03/2026 for $3,690.00, 16,300 shares on 03/04/2026 for $301,920.01, and 5,500 shares on 03/25/2026 for $104,229.40.

Does the Form 144 indicate how proceeds will be used?

No use-of-proceeds information is provided. The filing states the sale method as an exercise of stock options and that proceeds are to be for cash, without specifying any recipient or purpose.

Does this Form 144 confirm the sale has occurred?

No. Form 144 notifies a proposed sale; it does not confirm completion. Final execution and settlement would appear in subsequent trade confirmations or reporting filings if and when the sale occurs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:09 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034679
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Raben David
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Avenue 4th Floor New York NY 10010	5500	125830.01	65467187	04/27/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/27/2026	Exercise of Stock Options	Issuer			5500	04/27/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Raben 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116	Common	03/03/2026	200	3690.00
David Raben 116 Huntington Avenue Suite 703 Boston MA 02116	Common	03/04/2026	16300	301920.01
David Raben 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	03/25/2026	5500	104229.40

144: Remarks and Signature

Remarks
Date of Notice	04/27/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for David Raben
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)